Patients with EGFR-mutated NSCLC who progress on first-line osimertinib live longer without disease worsening when the drug is maintained alongside chemotherapy second line.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/osimertinibs-benefits-nsclc-can-extend-beyond-first-line-2025a1000nlc?src=rss
Author :
Publish date : 2025-09-07 19:20:00
Copyright for syndicated content belongs to the linked Source.
